Acadia Pharmaceuticals (ACAD) Long-Term Deferred Tax (2022 - 2026)

Acadia Pharmaceuticals' Long-Term Deferred Tax history runs 5 years deep, the most recent figure standing at $249.6 million for Q1 2026.

• On a quarterly basis, Long-Term Deferred Tax changed N/A year-over-year to $249.6 million in Q1 2026; TTM through Mar 2026 was $249.6 million, a N/A change from a year earlier, with the FY2025 full-year figure at $249.9 million, up 2772.17% from the prior year.
• Long-Term Deferred Tax steadied at $249.6 million in Q1 2026 per ACAD's latest filing, from $249.9 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $249.9 million in Q4 2025 and bottomed at $1.2 million in Q4 2022.
• The 5-year median for Long-Term Deferred Tax is $8.7 million (2024), against an average of $103.2 million.
• Across the five-year window, Long-Term Deferred Tax advanced 27.94% in 2024 and soared 2772.17% in 2025, its largest moves.
• Year by year, Long-Term Deferred Tax stood at $1.2 million in 2022, then soared by 466.67% to $6.8 million in 2023, then gained by 27.94% to $8.7 million in 2024, then surged by 2772.17% to $249.9 million in 2025, then retreated by 0.1% to $249.6 million in 2026.
• Per Business Quant, the three latest ACAD Long-Term Deferred Tax figures stand at $249.6 million (Q1 2026), $249.9 million (Q4 2025), and $8.7 million (Q4 2024).